AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the injectable Bydureon as a new formulation within the marketing authorization for Bydureon (extended release) for the treatment of type-2 diabetes.
The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen device which, in combination with other glucose-lowering medicines including basal insulin, aims to help improve glycaemic control in adults with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.
AstraZeneca has been focusing on diabetes, cancer and cardiovascular drugs as it works to build up its drug pipeline after losing billions of dollars in revenues as patents expired.
The latest recommendation is based on clinical trials.
This new formulation has been approved by the US Food and Drug Administration.
AstraZeneca has its U.S. headquarters near Wilmington and employs nearly 1,500 in northern Delaware.
